TrialBlood advances2025

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.

Pau Montesinos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.